Biocon Biologics Launches Nepexto for Autoimmune Diseases in Australia

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for treating autoimmune diseases like rheumatoid arthritis. With the support of local partner Generic Health, Nepexto aims to improve accessibility in Australia, building on its success across Europe.

Biocon Biologics, a subsidiary of Biocon, has strategically launched Nepexto, a biosimilar to the well-known Enbrel (Etanercept), in Australia to treat autoimmune conditions such as rheumatoid arthritis. The move marks a significant step in expanding the company's global reach within the immunology sector.

Partnering with Generic Health, a leader in providing high-quality generic medicines in Australia, Biocon aims to enhance patient access to Nepexto. This collaboration ensures that Australian patients will have access to effective treatment options for various autoimmune diseases.

Since its marketing authorisation in the EU in 2020, Nepexto has seen widespread adoption across Europe. Biocon Biologics is building on this momentum following its 2022 acquisition of the global biosimilars business, furthering its strategic expansion plans and enhancing its offerings in immunological treatments.

(With inputs from agencies.)